Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
2.100
-0.040 (-1.87%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
112
Market Cap
90.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
Dec 31, 2021 | 5.66M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 4 weeks ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 5 weeks ago - Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
- 7 weeks ago - Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PRNewsWire
- 2 months ago - KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire
- 2 months ago - Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Accesswire
- 2 months ago - Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX - PRNewsWire
- 3 months ago - KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire